SEC Form 4 · accession 0001203311-17-000014
SEATTLE GENETICS INC /WA · SGEN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Clay B Siegall
Officer — President and CEO · Director
Period of report
May 5, 2017
Accepted (ET)
May 9, 2017 · 7:42 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001060736
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 5, 2017 | M | 100 | $10.29 | A | 636,535 | D | |
| Common StockF2 | May 5, 2017 | S | 100 | $63.92 | D | 636,435 | D | |
| Common Stock | May 5, 2017 | M | 993 | $10.29 | A | 637,428 | D | |
| Common StockF3,F2 | May 5, 2017 | S | 993 | $62.82 | D | 636,435 | D | |
| Common Stock | May 5, 2017 | M | 9,330 | $10.29 | A | 645,765 | D | |
| Common StockF4,F2 | May 5, 2017 | S | 9,330 | $61.72 | D | 636,435 | D | |
| Common Stock | May 5, 2017 | M | 4,039 | $10.20 | A | 640,474 | D | |
| Common StockF5,F2 | May 5, 2017 | S | 4,039 | $61.47 | D | 636,435 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F6 | $10.20 | May 5, 2017 | M | 4,039 | D | — | May 25, 2017 | Common Stock | 4,039 | 0 | D |
| Non-Qualified Stock Option (right to buy)F7 | $10.29 | May 5, 2017 | M | 100 | D | — | Aug 28, 2017 | Common Stock | 100 | 41,582 | D |
| Non-Qualified Stock Option (right to buy)F7 | $10.29 | May 5, 2017 | M | 993 | D | — | Aug 28, 2017 | Common Stock | 993 | 40,589 | D |
| Non-Qualified Stock Option (right to buy)F7 | $10.29 | May 5, 2017 | M | 9,330 | D | — | Aug 28, 2017 | Common Stock | 9,330 | 31,259 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- F2Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
- F3Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $62.61 to $63.29. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F4Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $61.54 to $62.42. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F5Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $61.38 to $61.54. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F6Shares vested at a rate of 25% on 5/25/08 and monthly thereafter until all the shares were fully vested on 5/25/11.
- F7Shares vested at a rate of 25% on 8/28/08 and monthly thereafter until all the shares were fully vested on 8/28/11.